top of page

Peer Reviewed Publications

​

  1. Tsang V. The Role of Neoadjuvant RET Inhibitor in Medullary Thyroid Cancer. Clinical Thyroidology. Feb 2023 p71-74. https://doi.org/10.1089/ct.2023;35.71-74

  2. Li M, Chan DL, Tapia Rico G, Cehic G, Lawrence B, Wyld D, Pattison DA, Kong G, Hicks R, Michael M, Kiberu AD, Lim J, Clifton-Bligh R, Tsang V, Roach PJ, Leyden J, Diakos CI, Price TJ, Pavlakis N. Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT). Neuroendocrinology. 2022 Sep 1. doi: 10.1159/000526848. Epub ahead of print. PMID: 36049462.

  3. Percy KL, Ooi YX, Nahm CB, Simpson F, Hickey G, Sahni S, Chesher D, Itchins M, Pavlakis N, Tsang VH, Clifton-Bligh R, Gill AJ, Samra JS, Mittal A. Defining the rate of nutritional and metabolic derangements after pancreatic resection. Pancreatology. 2022 Aug 1:S1424-3903(22)00470-7. doi: 10.1016/j.pan.2022.07.014. Epub ahead of print. PMID: 35948507.

  4. Tsang V, Gill A, Gild M, Lurie B, Blumer L, Siddall R, et al. Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects. The Journal of clinical endocrinology and metabolism. 2022;107(9):e3824-e9.

  5. Muir CA, Tsang VHM, Menzies AM, Clifton-Bligh RJ. Immune Related Adverse Events of the Thyroid - A Narrative Review. Front Endocrinol (Lausanne). 2022;13:886930.

  6. Wu L, Tsang VHM, Sasson SC, Menzies AM, Carlino MS, Brown DA, et al. Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. Front Endocrinol (Lausanne). 2021;12:764138.

  7. Papachristos A, Do K, Tsang VH, Sywak M, Gill AJ, Sidhu S, et al. Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy. Thyroid. 2022;32(9):1086-93.

  8. Muir CA, Wood CC, Clifton-Bligh RJ, Long GV, Scolyer RA, Carlino MS, Menzies AM, Tsang VH 2022 Association of Antithyroid Antibodies in Checkpoint Inhibitor–Associated Thyroid Immune–Related Adverse Events. The Journal of Clinical Endocrinology & Metabolism.

  9. Gild ML, Tsang V, Clifton-Bligh RJ, Robinson BG 2021 (In press) Multiple Endocrine Neoplasia Type 2 and Medullary Thyroid carcinoma. In: Jameson J Larry DGL, (ed) Endocrinology: Adult and Paediatric. Vol. Saunders.

  10. Wu L, Tsang VH, Sasson SC, Menzies AM, Carlino MS, Brown DA, Clifton-Bligh R, Gunton JE 2021 Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. Frontiers in endocrinology 12.

  11. Tsang V and the Endocrine Subcommittee, Diabetes and Endocrinology Community of Practice, Agency for Clinical innovation.  Endocrinology prioritisation guided during COVID-19 1-6 (Pituitary Disease, Thyroid Surgery, Adrenal Gland Disorders, Bone Mineral Density, Endocrine Dynamic Testing, Radioactive Iodine).  https://aci.health.nsw.gov.au/__data/assets/pdf_file/0008/666953/ACI-COVID-Radioactive-iodine-I131-prioritisation.pdf

  12. Tsang V, Lau SL 2021 Secondary hypertension in three vignettes. Endocrinology Today 10(1):6.

  13. Sutherland R, Tsang V, Clifton‐Bligh RJ, Gild ML 2021 Papillary thyroid microcarcinoma: Is active surveillance always enough? Clinical endocrinology 95:811-817.

  14. Muir CA, Menzies AM, Clifton-Bligh RJ, Long GV, Scolyer RA, Tsang V 2021 Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors. Journal of the Endocrine Society 5:A876.

  15. Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VH, Menzies AM 2021 Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. The Journal of Clinical Endocrinology & Metabolism 106:e3704-e3713.

  16. Jonker PKC, Turchini J, Kruijff S, Lin JF, Gill AJ, Eade T, Aniss A, Clifton-Bligh R, Learoyd D, Robinson B, Tsang V, Glover A, Sidhu S, Sywak M 2021 Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment. Ann Surg Oncol.

  17. Jonker PK, Turchini J, Kruijff S, Lin JF, Gill AJ, Eade T, Aniss A, Clifton-Bligh R, Learoyd D, Robinson B Tsang V, Glover A, Sidhu S, Sywak M 2021 Correction to: Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment. Annals of surgical oncology 28:891.

  18. Jaffar S, Jayasekara J, Aniss AM, Tsang VHM, Learoyd DL, Clifton-Bligh R, Gill AJ, Glover AR, Sidhu SB, Robinson B, Sywak M 2021 Predicting distant metastatic disease in differentiated thyroid cancer: a matched case-control study. ANZ J Surg 91:716-723.

  19. Gild ML, Tsang VHM, Clifton-Bligh RJ, Robinson BG. Multikinase inhibitors in thyroid cancer: timing of targeted therapy. Nat Rev Endocrinol. 2021.

  20. Muir C C-BR, Long GV, Scolyer RA, Lo S, Tsang VHM, Menzies AM. Thyroid immune related adverse effects occurring in association with immune checkpoint inhibitor treatment. 2020 (In preparation).

  21. Wu L, Nahm CB, Jamieson NB, Samra J, Clifton-Bligh R, Mittal A, Tsang VHM. Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: A systematic review. Clinical endocrinology. 2020.

  22. Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, et al. Response to Letter to the Editor: "Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes". The Journal of clinical endocrinology and metabolism. 2020;105(6):e2317-8.

  23. Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, et al. Response to Letter to the Editor: "Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes". The Journal of clinical endocrinology and metabolism. 2020;105(6).

  24. Tsang VH, Gild M, Glover A, Clifton-Bligh R, Robinson BG. Thyroid cancer in the age of COVID-19. Endocrine-related cancer. 2020.

  25. Nylén C, Mechera R, Maréchal-Ross I, Tsang V, Chou A, Gill AJ, et al. Molecular Markers Guiding Thyroid Cancer Management. Cancers. 2020;12(8).

  26. Muir CA, Menzies AM, Clifton-Bligh R, Tsang VHM. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid. 2020.

  27. Lin M, Tsang V, Brewer J, Clifton-Bligh R, Gild ML. Infiltrative lymphocytic hypophysitis successfully treated with rituximab and mycophenolate mofetil. Endocrinol Diabetes Metab Case Rep. 2020;2020.

  28. Fuchs TL, Nassour AJ, Glover A, Sywak MS, Sidhu SB, Delbridge LW, Clifton-Bligh RJ, Gild ML, Tsang VHM Robinson BG, Clarkson A, Sheen A, SIoson L, Chou A, Gill AJ A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis. The American journal of surgical pathology. 2020.

  29. Clifford L GC, Tsang VH. Amiodarone Induced Thyrotoxicosis: When It Becomes a Storm. Endocrinology Today 2020;9(4):4.

  30. Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, et al. Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes. The Journal of clinical endocrinology and metabolism. 2019.

  31. Tsang VHM. Management of treatment-related toxicities in advanced medullary thyroid cancer. Current opinion in oncology. 2019;31(3):236-42.

  32. Tsang V CB. Endocrine immune related adverse events. Endocrinology Today. 2019.

  33. Lin M CB, Glastras S, Tsang VH. New onset hyperglycaemia in pregnancy. Endocrinology Today. 2019;8(4):5.

  34. Wijetunga A, Tsang V, Giuffre B. The Utility of Cross-Sectional Imaging in the Management of Suspected Scaphoid Fractures. Journal of Medical Radiation Sciences 2018.

  35. Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. European journal of endocrinology. 2018;178(2):175-82.

  36. LAU Sue Lynn, Tsang V. Recognising and correcting hyponatraemia in an elderly woman. Endocrinology Today. 2018;7(2):5.

  37. Jang HS, Parratt JDE, Tsang VHM, Coyle LA, Fernando SL. Serum vascular endothelial growth factor (VEGF) level can be used as a diagnostic marker in POEMS syndrome. Pathology. 2018;50(6):674-6.

  38. Gild ML, Tsang V, Samra J, Clifton-Bligh RJ, Tacon L, Gill AJ. Hypercalcemia in glucagon cell hyperplasia and neoplasia (Mahvash syndrome): a new association. The Journal of clinical endocrinology and metabolism. 2018.

  39. De Sousa SMC, Sheriff N, Tran CH, Menzies AM, Tsang VHM, Long GV, et al. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary. 2018.

  40. Wijewardene AA, Glastras SJ, Learoyd DL, Robinson BG, Tsang VHM. ACTH-secreting medullary thyroid cancer: a case series. Endocrinol Diabetes Metab Case Rep. 2017;2017.

  41. Sung J, Tsang V, Lau SL. Recurrent hypoglycaemia with reduced recognition. Endocrinology Today. 2017;6(4):5.

  42. Kam J, Tsang VH, Chalasani V. Retrograde Ejaculation: A Rare Presenting Symptom of Type 1 Diabetes Mellitus. Urol Case Rep. 2017;10:9-10.

  43. Bennett M LS, Tsang VH. Management of acute renal failure and hypercalcaemia. Endocrinology Today. 2017;6(1):31.

  44. Tsang VH, Robinson BG, Learoyd DL. The safety of vandetanib for the treatment of thyroid cancer. Expert Opin Drug Saf. 2016;15(8):1107-13.

  45. Logaraj A, Tsang VH, Kabir S, Ip JC. Adrenal crisis secondary to bilateral adrenal haemorrhage after hemicolectomy. Endocrinol Diabetes Metab Case Rep. 2016;2016.

  46. Lau SL, Tsang VH. A case of hyperglycaemia in a young woman using an insulin pump.. Endocrinology Today. 2016;5(2):5.

  47. Fraser S, Go C, Aniss A, Sidhu S, Delbridge L, Learoyd D, Clifton-Bligh R, Tacon L, Tsang V, Robinson B, Gill AJ, Sywak M BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. World journal of surgery. 2016;40(7):1618-24.

  48. Tsang VHM Robinson B. Update on thyorid cancer. Australian Thyroid Foundation Newsletter. 2015.

  49. Tsang VH, Tacon LJ, Learoyd DL, Robinson BG. Pheochromocytomas in Multiple Endocrine Neoplasia Type 2. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2015;204:157-78.

  50. Luttrell M, Chamption B, Tsang V. Managing an acute case of Addison's disease. Endocrinology Today. 2015;4(4):4.

  51. Kozusko K, Tsang VH, Bottomley W, Cho YH, Gandotra S, Mimmack M, et al. Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy. Diabetes. 2015;64(1):299-310.

  52. Kim E, Rath EM, Tsang VH, Duff AP, Robinson BG, Church WB, et al. Structural and functional consequences of succinate dehydrogenase subunit B mutations. Endocrine-related cancer. 2015;22(3):387-97.

  53. Gupta A, Champion B, Tsang VH. Managing an elderly woman with Graves' disease. Endocrinology Today. 2015;5(1):29-32.

  54. Tsang VH, Dwight T, Benn DE, Meyer-Rochow GY, Gill AJ, Sywak M, et al. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Endocrine-related cancer. 2014;21(3):415-26.

  55. Tsang V, Campbell, L. Catecho-Strophic Diabetic Ketoacidosis. The Best of Grand Rounds. Wiley-Blackwell Publishing Award for Clinical Excellence. Internal Medicine Journal. 2010;40(Suppl. 1):1.

bottom of page